Exagen INC 8-K filings

Exagen Inc. announced record revenue and test volumes for Q2 2026, alongside a reduced net loss and increased full-year revenue guidance.

Exagen Inc. announced the final voting results from its 2026 annual meeting of stockholders, including the election of two Class I directors and the ratification of its independent auditor.

Exagen Inc. announced record first quarter 2026 revenue of $17.3 million, a 12% increase year-over-year, alongside an improved adjusted EBITDA loss of $2.2 million.

Exagen Inc. announced the resignation of board member Ana Hooker, leading to a reduction in the board's size from eight to seven members.

Exagen Inc. announced preliminary unaudited financial results for 2025, reporting record full-year revenue and a significant increase in year-end cash.

Exagen Inc. announced record third-quarter 2025 revenue of $17.2 million, a 38% increase year-over-year, alongside improved operating and adjusted EBITDA losses.

Exagen Inc. announced record second-quarter 2025 revenue of $17.2 million, representing 14% year-over-year growth, alongside a $20.2 million public stock offering and new loan facility to bolster its financial position.

Exagen Inc. announced the appointment of Chas McKhann, a veteran life sciences leader with a track record of successful exits, to its Board of Directors, alongside an increase in board size and an update to its non-employee director compensation program.

Exagen Inc. announced that its stockholders approved all four proposals at the 2025 annual meeting, including the election of two Class III directors and the ratification of its independent accounting firm.

Exagen Inc. successfully closed a public offering of common stock, raising approximately $20.2 million in gross proceeds.

Exagen Inc. has priced its public offering of 3,350,000 shares of common stock at $5.25 per share, expecting gross proceeds of $17.6 million.

Exagen Inc. announced record total revenue of $15.5 million for Q1 2025, driven by increased average selling price and AVISE CTD test volume growth.

Exagen Inc. announces a new credit facility with Perceptive Advisors, providing $25 million upfront to refinance existing debt and potential for $50 million more for future growth.

Exagen Inc. reports record full-year revenue and improved profitability metrics for 2024, driven by increased average selling prices and operational efficiencies.

Exagen Inc. has received conditional approval in New York for new lupus and rheumatoid arthritis biomarkers and reported record preliminary full-year 2024 revenue and improved adjusted EBITDA.

Exagen Inc. announced its third quarter 2024 results, highlighting a 26% increase in the average selling price of its AVISE CTD test and reduced adjusted EBITDA losses.

Exagen Inc. announced record second-quarter revenue of $15.1 million and raised its full-year revenue and adjusted EBITDA guidance.

Exagen Inc. has appointed Jeffrey Black as its new Chief Financial Officer, effective September 1, 2024, while also naming John Aballi as Interim CFO.

Exagen Inc. has appointed Jeffrey Black as its new Chief Financial Officer, effective September 1, 2024, replacing Kamal Adawi, with John Aballi serving as interim CFO until then.

Exagen Inc. held its 2024 annual meeting of stockholders on June 10, 2024, where shareholders elected three Class II directors and ratified the appointment of BDO USA, P.C. as the company's independent auditor.

Exagen Inc. announced a 28.4% increase in revenue and a significant improvement in profitability for the first quarter of 2024, leading to raised full-year guidance.

Exagen Inc. has appointed Scott D. Kahn, Ph.D. to its Board of Directors while also reducing the board size from nine to seven members, effective June 10, 2024.

Exagen Inc. announced record full-year revenue of $52.5 million and a significant increase in gross margin, alongside a reduction in net loss and operating expenses for 2023.